DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics
- PMID: 27368114
- DOI: 10.1016/j.clinthera.2016.06.006
DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics
Abstract
Purpose: As a result of improved understanding of DNA repair mechanisms, poly(ADP-ribose) polymerase inhibitors (PARPi) are increasingly recognized to play an important therapeutic role in the treatment of cancer. The aim of this article is to provide a review of PARPi function in DNA damage repair and synthetic lethality and to demonstrate how these mechanisms can be exploited to provide new PARPi-based therapies to patients with solid tumors.
Methods: Literature from a range of sources, including PubMed and MEDLINE, were searched to identify recent reports regarding DNA damage repair and PARPi.
Findings: DNA damage repair is central to cellular viability. The family of poly(ADP-ribose) polymerase proteins play multiple intracellular roles in DNA repair, but function primarily in the resolution of repair of single-strand DNA breaks. Insights through the discovery of germline BRCA1/2 mutations led to the understanding of synthetic lethality and the potential therapeutic role of PARPi in the treatment of cancer. Further understanding of DNA damage repair and the concept of BRCA-like tumors have catalyzed PARPi clinical investigation in multiple oncologic settings.
Implications: PARPi hold great promise in the treatment of solid tumors, both as monotherapy and in combination with other cancer therapeutics. Multiple PARPi clinical trials are currently underway. Further understanding of aberrant DNA repair mechanisms in the germline and in the tumor genome will allow clinicians and researchers to apply PARPi most strategically in the era of personalized medicine.
Keywords: DNA damage; DNA repair; neoplasms; poly(ADP-ribose) polymerase inhibitors.
Copyright © 2016 Elsevier HS Journals, Inc. All rights reserved.
Similar articles
-
Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.J Exp Clin Cancer Res. 2016 Nov 24;35(1):179. doi: 10.1186/s13046-016-0456-2. J Exp Clin Cancer Res. 2016. PMID: 27884198 Free PMC article. Review.
-
PARPi focus the spotlight on replication fork protection in cancer.Nat Cell Biol. 2017 Oct 31;19(11):1309-1310. doi: 10.1038/ncb3638. Nat Cell Biol. 2017. PMID: 29087384
-
New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.Curr Treat Options Oncol. 2016 Mar;17(3):12. doi: 10.1007/s11864-015-0378-9. Curr Treat Options Oncol. 2016. PMID: 26931795 Free PMC article. Review.
-
Resurrection of PARP Inhibitors in Breast Cancer.J Natl Compr Canc Netw. 2018 Sep;16(9):1150-1156. doi: 10.6004/jnccn.2018.7031. J Natl Compr Canc Netw. 2018. PMID: 30181424 Review.
-
Triumphs and challenges in exploiting poly(ADP-ribose) polymerase inhibition to combat triple-negative breast cancer.J Cell Physiol. 2023 Aug;238(8):1625-1640. doi: 10.1002/jcp.31015. Epub 2023 Apr 12. J Cell Physiol. 2023. PMID: 37042191 Review.
Cited by
-
Pharmacotherapy for cervical cancer: current standard of care and new perspectives.Expert Opin Pharmacother. 2024 Aug;25(12):1591-1603. doi: 10.1080/14656566.2024.2395379. Epub 2024 Aug 27. Expert Opin Pharmacother. 2024. PMID: 39164924 Review.
-
Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells.J Am Soc Mass Spectrom. 2022 Feb 2;33(2):242-250. doi: 10.1021/jasms.1c00215. Epub 2021 Dec 27. J Am Soc Mass Spectrom. 2022. PMID: 34958553 Free PMC article.
-
Modulators of Redox Metabolism in Head and Neck Cancer.Antioxid Redox Signal. 2018 Dec 1;29(16):1660-1690. doi: 10.1089/ars.2017.7423. Epub 2017 Dec 20. Antioxid Redox Signal. 2018. PMID: 29113454 Free PMC article. Review.
-
The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study.Cancer Chemother Pharmacol. 2021 Jul;88(1):81-88. doi: 10.1007/s00280-021-04253-x. Epub 2021 Mar 27. Cancer Chemother Pharmacol. 2021. PMID: 33772633 Free PMC article. Clinical Trial.
-
Design of potential anti-tumor PARP-1 inhibitors by QSAR and molecular modeling studies.Mol Divers. 2021 Feb;25(1):263-277. doi: 10.1007/s11030-020-10063-9. Epub 2020 Mar 5. Mol Divers. 2021. PMID: 32140890
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous